AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Cocrystal Pharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001T107W2
0.95▲ 0.04 (4.17%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
0.91
Day's Range
0.92 – 1.07
52-Week Range
0.76 – 2.03
Volume
43.5K
Avg Volume
43.8K
Share Statistics
Shares Outstanding
Employees
10
Exchange
XNAS
Listed
2008-04-01
Share count as of August 13, 2026

Cocrystal Pharma, Inc. Common Stock (COCP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cocrystal Pharma, Inc. Common Stock (COCP)
What is Cocrystal Pharma, Inc. Common Stock's Market Cap?
Cocrystal Pharma, Inc. Common Stock's Market Cap is $18.3M, based on as-reported figures from SEC (XBRL) filings.
What is Cocrystal Pharma, Inc. Common Stock's Net Income (TTM)?
Cocrystal Pharma, Inc. Common Stock's Net Income (TTM) is -$9.9M, based on as-reported figures from SEC (XBRL) filings.
What is Cocrystal Pharma, Inc. Common Stock's EBITDA?
Cocrystal Pharma, Inc. Common Stock's EBITDA is -$10.1M, based on as-reported figures from SEC (XBRL) filings.
What is Cocrystal Pharma, Inc. Common Stock's Diluted EPS (TTM)?
Cocrystal Pharma, Inc. Common Stock's Diluted EPS (TTM) is -0.52, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · COCPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue and grant income:
Government contract revenue——
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
% of revenue3132.4%1147.1%——
Loss from operations
% of revenue-3032.4%-1047.1%——
Other income (expense):
Interest income, net
Foreign Currency Gain/Loss
Total other income, net
Net loss
% of revenue-3013.3%-1021.8%——
Earnings Per Share (Basic)
Earnings Per Share (Diluted)